Athenex Inc (NASDAQ:ATNX) shares hit a new 52-week low during trading on Friday . The stock traded as low as $13.04 and last traded at $13.20, with a volume of 11888 shares traded. The stock had previously closed at $13.52.
Several research analysts recently commented on ATNX shares. ValuEngine cut shares of Athenex from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. BidaskClub cut shares of Athenex from a “buy” rating to a “hold” rating in a report on Thursday, June 28th. Finally, Zacks Investment Research cut shares of Athenex from a “hold” rating to a “sell” rating in a report on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.75.
The firm has a market capitalization of $941.28 million, a P/E ratio of -5.79 and a beta of -1.67.
In other Athenex news, Director Song-Yi Zhang sold 102,734 shares of the stock in a transaction on Wednesday, August 22nd. The shares were sold at an average price of $17.24, for a total value of $1,771,134.16. Following the completion of the sale, the director now owns 4,000 shares in the company, valued at $68,960. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jinn Wu purchased 5,000 shares of the business’s stock in a transaction on Monday, August 20th. The stock was purchased at an average price of $17.20 per share, with a total value of $86,000.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at $68,800. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 27,000 shares of company stock valued at $405,120 and sold 344,317 shares valued at $5,859,972. Company insiders own 29.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of Athenex by 426.5% during the 1st quarter. Barclays PLC now owns 5,913 shares of the company’s stock worth $100,000 after buying an additional 4,790 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Athenex by 363.2% during the 2nd quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock worth $129,000 after buying an additional 5,434 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Athenex during the 1st quarter worth about $208,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Athenex during the 2nd quarter worth about $266,000. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Athenex during the 1st quarter worth about $289,000. Institutional investors own 19.83% of the company’s stock.
About Athenex (NASDAQ:ATNX)
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Further Reading: Outstanding Shares
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.